BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, May 4, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Sep. 8, 2010
View Archived Issues
Pooled Phase III Data Underline Microplasmin's Efficacy in VMA
Read More
Clinicians Seek New Fund for Pan-European Trials
Read More
DBV Wins Grant for Phase II of Peanut Allergy Desensitizer
Read More
Other News To Note
Read More
Santhera, Ipsen Sign $181M Collaboration for Fipamezole
Shares in Santhera Pharmaceuticals AG rose more than 8 percent Friday on news of a European partnering deal with Ipsen Group SA, worth up to €141 million (US$181 million), for its Parkinson's drug Fipamezole. (BioWorld International)
Read More
Forbion Closes $242M Fund for U.S., Israeli Investments
Read More